Absci (NASDAQ:ABSI) specializes in harnessing the power of synthetic biology to dramatically accelerate drug discovery and development. By integrating artificial intelligence and advanced biological techniques, the company works to revolutionize how proteins are produced and engineered, aiming to bring new, better therapeutics to market faster. Absci's projects primarily focus on creating highly-efficient, cost-effective drug production platforms that can significantly shorten the development time from concept to clinical trials. The company's overarching objective is to become a pivotal player in the biopharmaceutical industry by enabling the creation of novel medicines with their cutting-edge technology, ultimately improving patient outcomes and reducing healthcare costs.